Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
Receiving a diagnosis of Ductal Carcinoma In Situ (DCIS) is difficult. It isn’t really a cancer diagnosis but it is pre-cancer so what is the patient to do?
Most women who are diagnosed with DCIS have a lumpectomy- removing the DCIS cells. Undergoing local radiation reduces the risk of further breast cancer by about 15%.
However many newly diagnosed DCIS patients email me saying that they don’t want to undergo any toxic therapies.
I am a cancer survivor and cancer coach. My advice? Consider the gene test linked below to give you a more information of your risk of breast cancer. Also please consider cheap and easy ways to reduce your risk of breast cancer.
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
To download the DCIS Guide, click here.
To learn more about breast cancer, scroll down the page, post a question or comment and I will reply to you ASAP.
“DCIS is called “non-invasive” because it hasn’t spread beyond the milk duct into any normal surrounding breast tissue. DCIS isn’t life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on.
When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. The chances of a recurrence are under 30%.
Women who have breast-conserving surgery (lumpectomy) for DCIS without radiation therapy have about a 25% to 30% chance of having a recurrence at some point in the future. Including radiation therapy in the treatment plan after surgery drops the risk of recurrence to about 15%. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive (DCIS again) about half the time and invasive about half the time. (DCIS itself is NOT invasive.)”
“For women who have early breast tumors surgically removed, a new genetic test may help predict the odds of a recurrence, a new study says.
This refers to abnormal cells in the lining of the milk ducts (Ductal Carcinoma In-Situ or DCIS) that may or may not progress to cancer that invades the surrounding breast tissue. Because there is no way of foretelling a progression, surgery is usually performed to remove the abnormality.
In the new study, researchers looked at whether a new test that zeroes in on certain genes can help predict which women will have their ductal carcinoma in situ recur after surgery. The goal is to aid doctors and patients in deciding on further treatment.
Right now, surgery is often followed by radiation and, in some cases, the drug tamoxifen, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.
“But we’d all like to have a way to identify women who can avoid further treatment, and those who should have it,” said Lichtenfeld, who was not involved in the study.
But he stressed that the ultimate value of the test — known as Oncotype DX — is not yet known, even though it is already on the market.
The researchers found that among those surgery-only patients, the higher the carcinoma score, the greater the risk of a recurrence over the next decade. For each 50-point increase in the score, the odds of a recurrence doubled.”
The hope, Rakovitch said, is that the Oncotype test will help some women avoid “overtreatment,” while others can feel more confident that they need additional treatment after surgery.